论文部分内容阅读
目前最常用的筛选前列腺癌的肿瘤标记物是前列腺特异性抗原(PSA),但PSA特异性及对前列腺癌的早期诊断价值仍然存在争议,因此大量研究转向寻找新的前列腺癌标志物,已取得不少成果。目前认为前列腺癌抗原3基因、α-甲基酰基辅酶A消旋酶、TMPRSS2-ERG融合基因和微精原蛋白-β等肿瘤标记物对前列腺癌的早期诊断有较高的临床意义。本文将对前列腺特异性抗原(PSA)及其亚型、尿液中的生物学标记物(前列腺癌抗原3基因,α-甲基酰基辅酶A消旋酶,TMPRSS2-ERG融合基因和微精原蛋白-β)和其他新型的血清和尿液中的标志物研究现状作简要概述。
Currently the most commonly used tumor marker for screening for prostate cancer is prostate-specific antigen (PSA), but the specificity of PSA and the value of early diagnosis of prostate cancer remain controversial, and a large body of research has turned to finding new markers of prostate cancer that have been made A lot of results. Now that the prostate cancer antigen 3 gene, α-methylacyl-CoA racemase, TMPRSS2-ERG fusion gene and micro-sperm protein-β and other tumor markers for the early diagnosis of prostate cancer have a higher clinical significance. This article will prostate specific antigen (PSA) and its subtypes, urine biomarkers (prostate cancer antigen 3 gene, α-methyl acyl CoA racemase, TMPRSS2-ERG fusion gene and micro-sperm Protein-β) and other novel serum and urine markers.